Advanced Prostate Cancer Consensus Conference (APCCC) 2026

EMBARK Trial Data on Treatment Suspension in Non-Metastatic Prostate Cancer - Mika Matikainen

Adaptive Dosing of Lutetium PSMA Based on Imaging and PSA Response - Louise Emmett

Clinical Scenario and Patient Preference Guide Radium-223 Use in mCRPC - Daniel Heinrich

Patient Perspective on Radiographic Progression-Free Survival in Metastatic Prostate Cancer - David Matheson

Combination Approaches in Lutetium PSMA Therapy in mCRPC - Michael Hofman

Three Priority Targets Beyond PSMA for Prostate Cancer Radioligand Therapy - Ken Herrmann

AR Degraders, T-Cell Engagers, and EZH2 Inhibitors in Prostate Cancer Pipeline - Maha Hussain

Survey Results on Prostate Cancer Management Treatment Preferences in South Asia - Vedang Murthy

Bone-Modifying Agents in Prostate Cancer: Distinguishing Osteoporosis from Skeletal-Related Events - Matthew Smith

Nutritional Counseling for Prostate Cancer Patients Receiving Systemic Therapy - Maria De Santis

Examining the Role of Metastasis-Directed Therapy Alone Versus Combined Approaches in Oligometastatic Prostate Cancer - Kosj Yamoah

Salvage Radiotherapy in Prostate Cancer: Weighing the Role of Added Hormonal Therapy - Valerie Fonteyne

Debating Prostate Radiotherapy for Metastatic Hormone-Sensitive Prostate Cancer - Tyler Seibert

Testosterone Recovery Dynamics After Short-Term ADT for Localized Prostate Cancer - Bertrand Tombal

Balancing Treatment Intensification and Quality of Life in Elderly Prostate Cancer Patients - Rana McKay

Genomic Classifiers and AI for Personalizing Prostate Cancer Radiation Therapy - Jason Efstathiou

APCCC Consensus Meeting Focuses on Real-World Prostate Cancer Management - Silke Gillessen